{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:10:15Z","timestamp":1782601815965,"version":"3.54.5"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["anesthesiology.theclinics.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anesthesiology Clinics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.anclin.2017.01.007","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T01:21:55Z","timestamp":1490923315000},"page":"207-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Uterotonic Medications"],"prefix":"10.1016","volume":"35","author":[{"given":"Cristianna","family":"Vallera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn O.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anclin.2017.01.007_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1042\/bj0040427","article-title":"The action of extracts of the pituitary body","volume":"4","author":"Dale","year":"1909","journal-title":"Biochem J"},{"issue":"12","key":"10.1016\/j.anclin.2017.01.007_bib2","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1021\/ja01641a004","article-title":"Oxytocin: synthesis","volume":"76","author":"Du Vigneaud","year":"1954","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.anclin.2017.01.007_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1152\/physrev.2001.81.2.629","article-title":"The oxytocin receptor system: structure, function, and regulation","volume":"81","author":"Gimpl","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1016\/j.anclin.2017.01.007_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijoa.2010.04.011","article-title":"The use of uterotonic drugs during caesarean section","volume":"19","author":"Dyer","year":"2010","journal-title":"Int J Obstet Anesth"},{"key":"10.1016\/j.anclin.2017.01.007_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00003081-200009000-00006","article-title":"Pharmacology of oxytocin and prostaglandins","volume":"43","author":"Arais","year":"2000","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/ACO.0b013e328345331c","article-title":"Oxytocin for labour caesarean delivery: implications for the the anaesthesiologist","volume":"24","author":"Dyer","year":"2011","journal-title":"Curr Opin Anesthesiol"},{"issue":"2","key":"10.1016\/j.anclin.2017.01.007_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009332.pub2","article-title":"Intramuscular versus intravenous prophylactic oxytocin for the third sate of labour","author":"Oladapo","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anclin.2017.01.007_bib8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/jcem-50-2-397","article-title":"Oxytocin levels and disappearance rate and plasma follicle-stimulant hormone and luteinizing hormone after oxytocin infusion in men","volume":"50","author":"Dawood","year":"1980","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.anclin.2017.01.007_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0002-9378(84)90355-7","article-title":"Oxytocin augmentation of dysfunctional labor. IV. Oxytocin pharmacokinetics","volume":"150","author":"Seitchik","year":"1984","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1530\/ror.0.0030113","article-title":"Oxytocin: a paracrine hormone in the regulation of parturition?","volume":"3","author":"Mitchell","year":"1998","journal-title":"Rev Reprod"},{"issue":"1","key":"10.1016\/j.anclin.2017.01.007_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/bja\/ael302","article-title":"Haemodynamic effects of oxytocin given as IV bolus or infusion on women undergoing caesarean section","volume":"98","author":"Thomas","year":"2007","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.anclin.2017.01.007_bib12","doi-asserted-by":"crossref","first-page":"10005","DOI":"10.1097\/01.AOG.0000142709.04450.bd","article-title":"Oxytocin requirements at elective cesarean delivery: a dose-finding study","volume":"104","author":"Carvalho","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.AOG.0000191529.52596.c0","article-title":"Minimum oxytocin dose requirement after cesarean delivery for labor arrest","volume":"104","author":"Balki","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/356526a0","article-title":"Structure and expression of a human oxytocin receptor","volume":"356","author":"Kimura","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.anclin.2017.01.007_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/jrf.0.1200091","article-title":"Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour","volume":"120","author":"Phaneuf","year":"2000","journal-title":"J\u00a0Reprod Fertil"},{"issue":"1","key":"10.1016\/j.anclin.2017.01.007_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/ALN.0000000000000682","article-title":"A\u00a0randomized, double-blinded trial of a \u201crule of threes\u201d algorithm versus continuous infusion of oxytocin during elective cesarean delivery","volume":"123","author":"Kovacheva","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.anclin.2017.01.007_bib17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1054\/ijoa.2002.0970","article-title":"Haemodynamic changes caused by oxytocin during caesarean section under spinal anesthesia","volume":"11","author":"Pinder","year":"2002","journal-title":"Int J Obstet Anesth"},{"key":"10.1016\/j.anclin.2017.01.007_bib18","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1399-6576.2009.01964.x","article-title":"Oxytocin infusion: acute hyponatremia, seizures, and coma","volume":"53","author":"Begrum","year":"2009","journal-title":"Acta Anasthesiol Scand"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.007_bib19","first-page":"523","article-title":"Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology","volume":"56","author":"de Groot","year":"1998","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.007_bib20","first-page":"1039","article-title":"ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage","volume":"108","author":"American College of Obstetricians and Gynecologists","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib21","unstructured":"Novartis. Methergine (methylergonovine maleate). Injection Label. U.S. Food and\u00a0Drug Adminstration. 2012. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/006035s078lbl.pdf. Accessed August 31, 2016."},{"issue":"5","key":"10.1016\/j.anclin.2017.01.007_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5688\/aj700598","article-title":"Ergot and its alkaloids","volume":"70","author":"Schiff","year":"2006","journal-title":"Am J Pharm Educ"},{"issue":"1","key":"10.1016\/j.anclin.2017.01.007_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0301-2115(95)02531-6","article-title":"The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage","volume":"69","author":"de Groot","year":"1996","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.anclin.2017.01.007_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jchromb.2015.12.046","article-title":"A\u00a0sensitive LC-MS\/MS method to quantify methylergonovine in human plasma and its application to a pharmacokinetic study","volume":"1011","author":"Gao","year":"2016","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"9","key":"10.1016\/j.anclin.2017.01.007_bib25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/1933719112468951","article-title":"Which uterotonic is better to prevent the postpartum hemorrhage? Latest news in terms of clinical efficacy, side effects, and contraindications: a systematic review","volume":"20","author":"Gizzo","year":"2013","journal-title":"Reprod Sci"},{"key":"10.1016\/j.anclin.2017.01.007_bib26","doi-asserted-by":"crossref","first-page":"642.e1-7","DOI":"10.1016\/j.ajog.2015.01.008","article-title":"Second-line uterotonics and the risk of hemorrhage-related morbidity","volume":"212","author":"Butwick","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.anclin.2017.01.007_bib27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/head.12033","article-title":"Oral methylergonovine maleate for refractory migraine and cluster headache prevention","volume":"53","author":"Saper","year":"2013","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.anclin.2017.01.007_bib28","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/00000542-200404000-00055","article-title":"Myocardial ischemia induced by intramyometrial injection of methylergonovine maleate","volume":"100","author":"Kuczkowski","year":"2004","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.anclin.2017.01.007_bib29","doi-asserted-by":"crossref","first-page":"459.e1","DOI":"10.1016\/j.ajog.2013.07.001","article-title":"Methylergonovine maleate and the risk of myocardial ischemia and infarction","volume":"209","author":"Bateman","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.anclin.2017.01.007_bib30","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1213\/ANE.0000000000000398","article-title":"Patterns of second-line uterotonic use in a large sample of hospitalizations for childbirth in the United States: 2007-2011","volume":"119","author":"Bateman","year":"2014","journal-title":"Anesth Analg"},{"key":"10.1016\/j.anclin.2017.01.007_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0090-6980(89)90027-0","article-title":"Changes in plasma levels of PGF2\u03b1 and PGI2 metabolites at and after delivery at term","volume":"37","author":"Noort","year":"1989","journal-title":"Prostaglandins"},{"key":"10.1016\/j.anclin.2017.01.007_bib32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/0090-6980(82)90039-9","article-title":"The origin of circulating 13,14-dihydro-15-keto-prostaglandin F2\u03b1 during delivery","volume":"24","author":"Fuchs","year":"1982","journal-title":"Prostaglandins"},{"key":"10.1016\/j.anclin.2017.01.007_bib33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1521-6934(03)00043-9","article-title":"Pharmacokinetics of prostaglandins","volume":"17","author":"Bygdeman","year":"2003","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib34","first-page":"806","article-title":"Management of severe postpartum hemorrhage with a prostaglandin F2\u03b1 analogue","volume":"63","author":"Hayashi","year":"1984","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0028-2243(94)90154-6","article-title":"Some mechanical properties of skinned fibres of pregnant human myometrium","volume":"56","author":"Izumi","year":"1994","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.anclin.2017.01.007_bib36","unstructured":"Pfizer. Hemabate (carboprost tromethamine). U.S. Food and Drug Administration. 2013. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/017989s019lbl.pdf. Accessed August 22, 2016."},{"key":"10.1016\/j.anclin.2017.01.007_bib37","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1471-0528.1991.tb13469.x","article-title":"Use of intra myometrial 15-methyl prostaglandin F2\u03b1 to control atonic postpartum haemorrhage following vaginal delivery and failure of conventional therapy","volume":"98","author":"Bigrigg","year":"1991","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0959-289X(94)90213-5","article-title":"Severe bronchospasm and hypotension after 15-methyl prostaglandin F2\u03b1 in atonic postpartum haemorrhage","volume":"3","author":"O\u2019Leary","year":"1994","journal-title":"Int J Obstet Anesth"},{"key":"10.1016\/j.anclin.2017.01.007_bib39","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/thx.31.6.685","article-title":"Pattern of total and regional lung function in subjects with bronchoconstriction induced by 15-methyl PGF2\u03b1","volume":"31","author":"Andersen","year":"1976","journal-title":"Thorax"},{"key":"10.1016\/j.anclin.2017.01.007_bib40","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/0002-9378(94)90160-0","article-title":"Bronchospasm after intramuscular 15-methyl prostaglandin F sub 2 alpha, 125 micrograms, and intravenous oxytocin, 20 units, for the control of blood loss at elective cesarean section","volume":"171","author":"Cooley","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1471-0528.2006.01227.x","article-title":"Life-threatening bronchospasm after intramuscular carboprost for postpartum hemorrhage","volume":"114","author":"Harper","year":"2007","journal-title":"BJOG"},{"key":"10.1016\/j.anclin.2017.01.007_bib42","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.ijgo.2007.09.004","article-title":"Misoprostol. Pharmacokinetic profiles, effects on the uterus, and side-effects","volume":"99","author":"Tang","year":"2007","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.anclin.2017.01.007_bib43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/humrep\/17.2.332","article-title":"Pharmacokinetics of different routes of administration of misoprostol","volume":"17","author":"Tang","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.anclin.2017.01.007_bib44","unstructured":"GD Searle & Co. Cytotec\u00ae (misoprostol). U.S. Food and Drug Administration. 2002. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/19268slr037.pdf. Accessed August 12, 2016."},{"key":"10.1016\/j.anclin.2017.01.007_bib45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0029-7844(97)00111-7","article-title":"Absorption kinetics of misoprostol with oral or vaginal administration","volume":"90","author":"Zieman","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.AOG.0000230398.32794.9d","article-title":"Misoprostol administered by epithelial routes","volume":"108","author":"Meckstroth","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.contraception.2004.06.014","article-title":"Comparison of misoprostol plasma concentrations following buccal and sublingual administration","volume":"71","author":"Schaff","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.anclin.2017.01.007_bib48","first-page":"968","article-title":"Pharmacokinetics and adverse-effect profile of rectally administered misoprostol in the third stage of labor","volume":"101","author":"Khan","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0301-2115(02)00355-X","article-title":"The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration","volume":"108","author":"Abdel-Aleem","year":"2003","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.anclin.2017.01.007_bib50","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.ajog.2004.05.008","article-title":"Misoprostol versus methylergometrine: pharmacokinetics in human milk","volume":"191","author":"Vogel","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.anclin.2017.01.007_bib51","series-title":"Fact sheets: uterotonic drugs for the prevention and treatment of postpartum hemorrhage","author":"POPPHI","year":"2008"},{"key":"10.1016\/j.anclin.2017.01.007_bib52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0020-7292(02)00020-6","article-title":"Preventing postpartum hemorrhage in low-resource settings","volume":"77","author":"McCormick","year":"2002","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 2","key":"10.1016\/j.anclin.2017.01.007_bib53","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.ijgo.2007.09.013","article-title":"Treatment of postpartum hemorrhage with misoprostol","volume":"99","author":"Blum","year":"2007","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"10.1016\/j.anclin.2017.01.007_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003249.pub3","article-title":"Treatment for primary postpartum hemorrhage","author":"Mousa","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anclin.2017.01.007_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijgo.2012.08.004","article-title":"Misoprostol for preventing and treating postpartum hemorrhage in the community: a closer look at the evidence","volume":"119","author":"Oladapo","year":"2012","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.anclin.2017.01.007_bib56","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2471\/BLT.08.055715","article-title":"Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects","volume":"87","author":"Hofmeyr","year":"2009","journal-title":"Bull World Health Organ"},{"issue":"7","key":"10.1016\/j.anclin.2017.01.007_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008982.pub2","article-title":"Postpartum misoprostol for preventing maternal mortality and morbidity","author":"Hofmeyr","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anclin.2017.01.007_bib58","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1471-0528.1999.tb08266.x","article-title":"Misoprostol dose-related shivering and pyrexia in the third stage of labour. WHO Collaborative Trial of Misoprostol in the Management of the Third Stage of Labour","volume":"106","author":"Lumbiganon","year":"1999","journal-title":"BJOG"},{"issue":"5","key":"10.1016\/j.anclin.2017.01.007_bib59","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1213\/ANE.0b013e3181d74898","article-title":"The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries","volume":"110","author":"Bateman","year":"2010","journal-title":"Anesth Analg"}],"container-title":["Anesthesiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1932227517300125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1932227517300125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T11:57:53Z","timestamp":1568980673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1932227517300125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1932227517300125"],"URL":"https:\/\/doi.org\/10.1016\/j.anclin.2017.01.007","relation":{},"ISSN":["1932-2275"],"issn-type":[{"value":"1932-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uterotonic Medications","name":"articletitle","label":"Article Title"},{"value":"Anesthesiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anclin.2017.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}